


I hereby certify that this correspondence is being
deposited with the United States Postal Service
first class mail in an envelope addressed to:
Mail Stop RCE, Commissioner for Patents, PO Box 1450
Alexandria, VA 22313-1450, on August 5, 2004

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By


Evelyn Gomez

Attorney Docket No. 407J-895030US
Client Ref. No. 98-232-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

James D. Marks, et al.

Application No.: 09/250,056

Filed: February 12, 1999

For: INTERNALIZING ErbB2
ANTIBODIES

Examiner: Larry R. Helms

Art Unit: 1642

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

08/11/2004 BABRAHA1 00000078 500893 09250056

03 FC:1806

180.00 DA


This IDS is being filed after the mailing date of the first Office Action and more than three months after the filing date, but prior to the Notice of Allowance or Final Office Action. Please deduct \$180.00, pursuant to 37 CFR §1.17(p), from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in cursive script that reads "Angela P. Horne, Ph.D.".

Angela P. Horne, Ph.D.
Reg. No. 41.079

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/250,056
Filing Date	February 12, 1999
First Named Inventor	James D. Marks
Group Art Unit	1642
Examiner Name	Larry R. Helms
Attorney Docket Number	407J-895030US
Date Submitted	August 5, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	1	WO	92/22653	A	Genentech, Inc.	12-23-1992		
	2	WO	96/21007	A	Chiron Viagene, Inc.	07-11-1996		
	3	WO	97/00271	A	University of California	01-03-1997		
	4	WO	97/10330	A	BiolInvent Int AB	03-20-1997		
	5	WO	97/38723	A	Immusol, Inc.	10-23-1997		
	6	WO	97/45544	A	Medical Res Council	12-04-1997		
	7	WO	98/05344	A	Brigham & Womens Hospital	02-12-1998		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	8	HOLT ET AL. (2003) "Domain antibodies: proteins for therapy." <i>Trends in Biotechnology</i> 21(11): 484-490.	
	9	HOOGENBOOM et al. (1998) "Antibody phage display technology and its applications." <i>Immunology</i> 4(1): 1-20.	
	10	HURWITZ ET AL. (1995) "Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake." <i>Proceedings of the National Academy of Sciences USA</i> 92(8): 3353-3357.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.